Procedures were performed either under conscious sedation or general anesthesia. Using femoral venous and arterial access multipolar electrode catheters were positioned in the coronary sinus to GCV, the right ventricular (RV) apex and the His bundle region. For the patients Background-Catheter ablation for ventricular arrhythmia (VA) near the distal great cardiac vein (GCV) is often challenging, and data are limited. Methods and Results-Analysis was performed in 30 patients (19 men; age, 52.8±15.5 years) who underwent catheter ablation for focal VA (11 ventricular tachycardia and 19 premature contractions) with early activation in the GCV (36.7±8.0 ms pre-QRS). Angiography in 27 patients showed earliest GCV site within 5 mm of a coronary artery in 20 (74%). Ablation was performed in the GCV in 15 patients and abolished VA in 8. Ablation was attempted at adjacent non-GCV sites in 19 patients and abolished VA in 5 patients (4 from the left ventricular endocardium and 1 from the left coronary cusp); all success had VA with an initial r wave in lead I and activation ≤7 ms after the GCV (GCV-non-GCV interval). In 13 patients, percutaneous epicardial mapping was performed, but because of adjacent coronaries only 2 received radiofrequency application with VA elimination in 1. Surgical cryoablation was performed in 3 patients and abolished VA in 2. Overall acute success was achieved in 16 (53%) patients. After a median of 2.8 months, 13 patients remained free of VA. Major complications occurred in 4 patients, including coronary injury requiring stenting. Conclusions-Ablation for this arrhythmia is challenging and often limited by the adjacent coronary vessels. Success of anatomically guided endocardial ablation may be identified by a short GCV-non-GCV interval and r wave in lead I. (Circ Arrhythm Electrophysiol. 2014;7:906-912.)
C atheter ablation (CA) for ventricular arrhythmia (VA) is a widely accepted therapy for patients without structural heart disease, but the approach and outcomes depend on the site of arrhythmia origin. 1 Most VAs originate from the right or left ventricular (LV) outflow regions, including myocardium around the aortic cusps and the summit of the LV. Approaches to ablation of VA from specific areas are being increasingly refined. Ablation of VA originating from near the distal great cardiac vein (GCV) is often difficult because of proximity to coronary arteries limited capability of radiofrequency energy application in the GCV itself. [2] [3] [4] [5] We have targeted these arrhythmias from various approaches, including the endocardial, epicardial via the GCV, and pericardial space, and also with open-chest surgery. The aim of this study was to evaluate the mapping features, outcomes, and risks for ablation of these VAs.
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Methods
Patient Characteristics
Of 270 patients (133 men; 49.2±14.0 years) without structural heart disease who underwent CA for focal VA from January 2006 to January 2014, 30 patients (19 men; age, 52.8±15.5 years) with VA (11 with ventricular tachycardia [VT] and 19 with premature ventricular contractions [PVC]) for which the earliest activation site before pericardial mapping was in the GCV were analyzed. In 25 patients, there was no evidence of structural heart disease. One patient had a history of anthracycline chemotherapy and later developed cardiomyopathy. The remaining 4 patients had a history of LV dysfunction felt to be PVC induced. Each patient gave written informed consent. Studies and data collection were performed according to protocols approved by the Human Research Committee of Brigham and Women's Hospital.
with a history of sustained VT, programmed ventricular stimulation was performed with ≤3 extrastimuli scanned to a minimum coupling interval of 180 ms after basic drives of 600 and 400 ms from 2 RV sites and burst pacing. If sustained VT was not reliably inducible, nonsustained VT or PVCs felt likely to be originating from the same site were targeted. Intravenous infusion of isoproterenol and epinephrine was administered as needed for arrhythmia induction.
Mapping and ablation were performed using a 3.5-mm tip catheter (NaviStar ThermoCool or ThermoCool SF; Biosense Webster, Diamond Bar, CA) in 25 patients. In 5 patients, a 4-mm-tip nonirrigated catheter (NaviStar; Biosense Webster) was used initially for mapping (5 patients) and attempted ablation (3 patients) before switching to an irrigated tip catheter. Activation mapping of VT or PVCs used an electroanatomic mapping system (CARTO 3 or XP; Biosense Webster) with bipolar electrograms high-pass filtered at 20 to 30 Hz and low-pass filtered at 400 Hz. Bipolar electrograms were also band pass filtered from 30 to 500 Hz and digitally recorded along with a 12-lead surface ECG (Cardiolab EP system; General Electric Healthcare, Buckinghamshire, United Kingdom). Pace mapping used unipolar stimuli at 10 mA and pulse width of 2 ms. 6 Epicardial mapping was considered if a subepicardial VT origin was suspected based on endocardial and GCV mapping, either at the same or a subsequent session. Percutaneous subxiphoid epicardial access was obtained as previously described either before administration of systemic anticoagulation or after anticoagulation was reversed. 7
Ablation
Coronary angiography was performed before initial ablation at sites with the possibility of an adjacent artery. If the distance of the catheter tip to a major coronary artery was <4 to 5 mm, radiofrequency delivery was avoided. Radiofrequency application was also not attempted if there was diaphragmatic capture during pacing from the ablation catheter. Irrigated radiofrequency energy was delivered at 25 to 50 W targeting an impedance drop of 10 to 20 Ω. At endocardial sites below the aortic valve, applications were usually repeated until unipolar pacing at 10 mA at 2 ms stimulus strength failed to capture. 6 At target areas in the sinuses of Valsalva and GCV, power exceeding 35 W was avoided. At some sites where radiofrequency ablation was limited or coronary artery proximity was of concern, ablation with a 6-mm-tip cryocatheter (Cryocath Technologies, Montreal, Canada) was attempted.
At the end of the procedure, the same induction protocol was repeated. Acute success was defined as the absence of any target arrhythmia.
Data Collection and Follow-Up
Data were collected from a centralized system containing records of all patients treated and followed up at Brigham and Women's Hospital and all associated Partners Healthcare sites. These records include emergency department visits, outpatient clinic visits, data recorded during inpatient care, and follow-up progress notes from referring physicians monitoring out-of-area patients. Referring physicians were contacted for clinical follow-up if necessary. Procedure success was defined as more than an 80% reduction in VA on 24-hour Holter monitoring or resolution of symptoms with no VA in all electrocardiograms during follow-up.
Statistical Analysis
Continuous variables were expressed as mean±SD values or median and interquartile ranges are shown in parentheses, as appropriate. Student t test or Mann-Whitney U test was used to compare continuous variables, depending on whether the values were normally distributed, and the χ 2 test was used to compare dichotomous variables unless the expected values in any cells were <5, in which case Fisher exact test was used. P<0.05 was considered to be statistically significant. Statistical analyses were performed with JMP 9 software (SAS Institute, Cary, NC).
Results
Electrophysiological Characteristics
Patient and arrhythmia characteristics are shown in Table 1 . Examples of VA morphology are shown in Figure I in the Data Supplement. Sustained VT was inducible in 10 of 11 patients who had a history of sustained VT. The lead V1 morphology was right bundle branch block like in 21 (70%) and left bundle branch block morphology with precordial transition before V3 in 8 (27%) and after V3 in 1 (3%). All VAs had an inferior axis (98.6°±10.0°). QRS duration was 161.9±18.8 ms ( Table 1 ). The maximum deflection index defined as the interval from the earliest QRS onset to the earliest R-wave peak in the precordial leads divided by the QRS duration 8 was >0.55, suggesting epicardial origin, in 10 (33%) patients, with a mean of 0.52±0.06. Previous ablation attempts had failed in Values are the mean±SD, median (25th, 75th interquartile range) or n (%). EPS indicates electrophysiological study; GCV, great cardiac vein; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MDI, maximum deflection index; PVC, premature ventricular contraction; RBBB, right bundle branch block; RFA, radiofrequency ablation; VA, ventricular arrhythmia; and VT, ventricular tachycardia. Figure IIA in the Data Supplement). In the remaining 3 (12%) patients, an 11 of 12 lead pace-map match was observed. In 3 patients, pacing at the earliest GCV site failed to capture the ventricular myocardium even with the strength of 10 mA and pulse width of 9 ms.
Mapping and Ablation in the GCV
A flow chart indicating procedure details is shown in Figure  III in the Data Supplement. In 3 patients, an ablation catheter could not be advanced to the distal GCV. Coronary venography and angiography were performed in the remaining 27 patients. In 7 patients (23%), the target site in the distal GCV was ≥5 mm distant from any coronary artery and ablation was performed, successfully abolishing the VA in 5 patients ( Figure 1C-1E ). In 8 of remaining 20 patients in whom the target site in the distal GCV was <5 mm from the coronary artery ( Figure IIC and IID in the Data Supplement), ablation was attempted at a region 2 to 3 mm proximal to the target site with elimination of VA in 3 patients. For all GCV radiofrequency ablation applications, the average radiofrequency power was 23 (interquartile range, 15-27) W and duration was 30 (interquartile range, 23-39) s, limited by an impedance rise that typically began after 15 to 20 s starting from a relatively high initial impedance of 244 (interquartile range, 186-266) Ω. In 4 patients, cryoablation in GCV was attempted because of low power and high impedance with failure of radiofrequency ablation in 3 patients and for reinforcement of an acutely successful radiofrequency ablation in 1. Cryoapplication of −80°C freezes was performed for 4 to 8 minutes, successfully abolishing the VA in 2 patients.
Characteristics of patients for whom radiofrequency energy was delivered in the GCV are shown in the Table in the Data Supplement. The surface ECG of the VA morphology, including R-S in lead I, R ratio in lead III/II, and Q ratio in aVL/ aVR, suggested that the VA origin was more leftward in the patients with successful ablation in the GCV when compared with patients in whom ablation in the GCV failed. The maximum deflection index was greater in those with successful ablation. However, there were no differences in the radiofrequency power and duration and initial impedance between the 2 groups. 
Endocardial Ablation Outside the GCV
In all patients additional non-GCV mapping was performed before successful GCV ablation or after GCV ablation failed; in the RV in all and in the LV cavity and the aortic sinus in 26 patients, respectively. Radiofrequency was applied at the earliest RV site in 4 patients and failed to abolish VA in all. In the LV and the aortic sinus, the earliest ventricular activation preceded the surface QRS onset by 20.9±6.6 ms and none had a perfect pace-map (Figure 2A and 2B ; Figure IIA and IIB in the Data Supplement). In 4 of 12 (33%) patients who had radiofrequency application below the aortic-mitral continuity and 1 of 5 (20%) patients who had radiofrequency application in left coronary cusp (LCC), VA was successfully abolished, despite later activation at these sites that in the GCV (Figure 2C and 2D) . Ablation failed at endocardial LV sites or the aortic sinus in 10 patients.
As shown in Table 2 , all patients with successful LV endocardial or LCC ablation had a VA morphology with an initial r wave in lead I when compared with 33% of patients with ablation failure at these sites (P=0.01). Furthermore, patients with successful LV endocardial or LCC ablation tended to have later activation times at the GCV (31.0±5.0 versus 38.1±8.7 ms preceding surface QRS; P=0.09) and the activation times at the earliest LV endocardial or LCC sites tended to be earlier (25.8±4.0 versus 19.6±6.6 ms preceding surface QRS; P=0.06) when compared with patients with ablation failure at these sites. Thus, the interval between the GCV site and earliest LV endocardial or LCC site activation during the VA (GCV-non-GCV interval) was shorter for those with successful endocardial ablation when compared with those in whom ablation failed (5.8±1.6 versus 18.9±8.5 ms; P=0.003; Table 2 ) and was ≤7 ms in all. There were no differences in pace-map morphology for those with successful versus unsuccessful endocardial ablation.
Percutaneous Epicardial Ablation
Percutaneous epicardial mapping from the pericardial space was performed in 13 patients and revealed sites where the earliest ventricular activation preceded onset of surface QRS by 29.1±6.3 ms ( Figure IIB in the Data Supplement); and 2 patients had sites that were slightly earlier than that of the GCV (by ≈2 ms in both). At the earliest epicardial site, a perfect pace-map was acquired in 2 of 10 patients, despite slightly later activation (by ≈2 ms) than the GCV ( Figure IIA in the Data Supplement). Coronary angiography was repeated during epicardial mapping in 10 patients; no ablation was performed because of the proximity to a coronary artery in 8 (80%) patients ( Figure IID in the Data Supplement). Radiofrequency ablation was performed in 2 patients (20%) with elimination of VA in 1 (10%). No cryoablation was performed.
Complications of CA
Major complication occurred in 3 patients. Coronary artery occlusion requiring stenting of a marginal branch of the circumflex artery occurred in 2 who received average radiofrequency energies of 23 and 27 W at ablation sites felt to be 2 mm and 5 to 7 mm distant from the vessel, respectively. GCV perforation without tamponade occurred in 1 patient.
Open-Chest Surgical Epicardial Ablation
In 3 patients who failed percutaneous CA, open-chest cryothermal surgical epicardial ablation with direct vision through a median sternotomy was subsequently performed. After dissection to reach the GCV area, freezes performed under direct visualization successfully abolished the VA in 2 patients. In the remaining patient, ablation was limited because of the vasospasm of the left anterior descendant and difficulty in fully dissecting the left anterior descendant. Furthermore, angina developed several months after the procedure; angina and angiography revealed a stenosis in the left anterior descendant at the site of cryoablation that was treated with a drug-eluting stent. 9
Acute Success and Long-Term Success During Follow-Up
Overall acute success was achieved in 16 (53%) patients; 8 in GCV, 4 at aortic-mitral continuity, 1 in LCC, 1 in pericardium space, and 2 with surgical ablation. In these patients, 1 patient who had incessant VT before ablation procedure resumed low-dose amiodarone for 2 months.
After a median follow-up of 2.8 (0.9-26.5) months in these 16 patients, procedure success was evaluated by 24-hour Holter in 7 patients (2 with VT and 5 with PVCs) and clinical symptom and electrocardiography in 9 (7 with symptomatic VTs and 2 with symptomatic recurrent PVCs) patients. Thirteen patients (81%) were free of VA; VA recurred in 3 patients (19%), which had been ablated in the GCV in 1, from the endocardium at the aortic-mitral continuity in 1, and from the pericardial space in 1.
Discussion
CA of VA originating from near the GCV is often challenging. However, in 5 of 7 patients (71%), in whom radiofrequency application was effectively delivered in the GCV, VA was successfully eliminated. During follow-up, 88% of patients in whom VA was successfully ablated in the GCV were free from VA recurrence. Therefore, acute and long-term success can be favorable if radiofrequency application can successfully be performed. [2] [3] [4] [5] Unfortunately, ablation is often not possible. In some cases, it is not possible to advance an ablation catheter to the distal GCV. Probably, the most important risk when delivering radiofrequency energy in the GCV is coronary artery injury. Coronary artery damage may be evident acutely or may not become manifest until several weeks after the procedure. 10, 11 The minimal safe distance between ablation sites and coronary arteries is not clear. It is likely that tissue contact, power, duration, and coronary blood flow all influence the risk. During angiography, cardiac motion can make the distance and time spent between the ablation catheter and the coronary arteries difficult to assess. Distances of 5 to 12 mm between the catheter tip and the coronary artery may be needed to avoid any risk of injury. 7 Inability to deliver sufficient radiofrequency energy because of high impedance and limited cooling from surrounding blood flow likely contributes to limit the effectiveness of ablation in the GCV. Cooling the saline infusion has been suggested 12 but was not assessed in this study. In the GCV, impedance was typically high and began increasing further within 25 s of radiofrequency delivery. In our experience attempted, additional radiofrequency applications at the same site after an initial impedance rise typically produce an even more rapid impedance rise. Occasionally, the GCV is of sufficient size to allow longer radiofrequency applications. More leftward VA origin in the patients with successful ablation in the GCV might indicate that the origin in the GCV was relatively proximal where the vessel size was sufficiently large to allow greater power. Radiofrequency power was not, however, statistically different between the patients with and without successful ablation in the GCV in this small study. Cryoablation can be considered because it is not limited by high impedance and is likely facilitated by low blood flow. Freezing also seems less likely to damage adjacent coronary arteries. 13 However, the cryocatheter can be difficult to maneuver in the coronary venous system.
When ablation in the GCV was not feasible or failed, we attempted to ablate at the best identifiable endocardial sites. In 20% of patients who underwent additional non-GCV mapping, including endocardial LV and the aortic sinus, radiofrequency application at the site closest to the early GCV site successfully eliminated the VA, despite later activation at these sites. Interestingly, in those patients the GCV-non-GCV interval was shorter for successful endocardial LV or LCC ablation sites when compared with unsuccessful ablation at these sites. In all patients with successful endocardial ablation the GCVnon-GCV interval was ≤7 ms, suggesting closer proximity to the VA origin than at failed sites. A possible mechanism of the shorter GCV-non-GCV interval in the successful endocardial ablation group is shown in Figure IV in the Data Supplement. Furthermore, all VA successfully ablated from endocardial LV or LCC had an initial r wave in lead I. Hence, those 2 features suggest that VA origin might be located relatively closer to the endocardium and might be predictors for the successful ablation from those sites. Pace-mapping at the LV endocardium was not a reliable marker for successful ablation. These observations are similar to those of Jauregui Abularach et al, 14 who reported successful ablation from the LV endocardium from the left sinus of Valsalva, LV endocardium, or both sites in 9 of 16 in a similar group of patients.
Epicardial mapping was also limited in this patient population. Sedation and anesthesia as is generally used for epicardial procedures can suppress arrhythmias although we did not encounter this as a significant issue in the present small series. The GCV area is often covered by fat and the overlying left atrial appendage and coronary arteries are present. Further rightward from the GCV, the LV myocardium is beneath the RV outflow. 5 In only 1 patient (8%) in whom radiofrequency energy was delivered from the pericardial space, the VA was acutely abolished but later recurred during follow-up.
Open-chest surgical epicardial ablation successfully eliminated VA in 2 of 3 patients (67%). A direct cardiac surgical approach can offer a potential solution for these VAs; deep lesions can be achieved with surgical application of cryoablation, which achieves temperatures substantially colder (≤−160°C) than those that can be achieved with present catheter cryoablation, and coronary arteries can be avoided under direct vision or occasionally mobilized for ablation of tissue beneath the vessel. 15, 16 However, surgical morbidity is a concern. Coronary injury is also possible. Mapping to identify the ablation target can be difficult in the operating room, and anesthesia can suppress the arrhythmia. 17
Limitations
This is a retrospective descriptive case series, with a relatively small number of patients. Patients were referred for ablation and 16 had failed before ablation attempts.
